A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
Status:
Terminated
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of
SGN-75 in combination with everolimus in patients with CD70-positive metastatic renal cell
carcinoma.